CDK4 and breast carcinoma: The cell cycle checkpoint module is of particular interest, because CDK4/6 inhibitors (CDK4/6i) are currently being used to treat ER+ breast cancer (50), but there is a dearth of reliable biomarkers for the efficacy of this treatment (51, 52).